Compare DUO & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DUO | TNON |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | China | United States |
| Employees | N/A | 27 |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 9.4M |
| IPO Year | 2018 | N/A |
| Metric | DUO | TNON |
|---|---|---|
| Price | $1.13 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 47.8K | ★ 138.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $19.56 |
| Revenue Next Year | N/A | $71.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.64 |
| 52 Week High | $5.34 | $5.85 |
| Indicator | DUO | TNON |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 46.44 |
| Support Level | $1.01 | $0.72 |
| Resistance Level | $1.20 | $0.89 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 42.66 | 45.43 |
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.